PMC:7755033 / 5246-6366 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"132","span":{"begin":355,"end":360},"obj":"Gene"},{"id":"133","span":{"begin":241,"end":247},"obj":"Species"},{"id":"134","span":{"begin":517,"end":534},"obj":"Species"},{"id":"135","span":{"begin":651,"end":659},"obj":"Species"},{"id":"136","span":{"begin":725,"end":733},"obj":"Species"},{"id":"137","span":{"begin":794,"end":799},"obj":"Species"},{"id":"138","span":{"begin":898,"end":905},"obj":"Species"},{"id":"139","span":{"begin":930,"end":934},"obj":"Species"},{"id":"140","span":{"begin":1050,"end":1058},"obj":"Species"},{"id":"141","span":{"begin":363,"end":382},"obj":"Chemical"},{"id":"142","span":{"begin":384,"end":405},"obj":"Chemical"},{"id":"143","span":{"begin":407,"end":416},"obj":"Chemical"},{"id":"144","span":{"begin":421,"end":428},"obj":"Chemical"},{"id":"145","span":{"begin":592,"end":611},"obj":"Chemical"},{"id":"146","span":{"begin":192,"end":200},"obj":"Disease"},{"id":"147","span":{"begin":227,"end":235},"obj":"Disease"},{"id":"148","span":{"begin":543,"end":552},"obj":"Disease"},{"id":"149","span":{"begin":633,"end":641},"obj":"Disease"},{"id":"150","span":{"begin":642,"end":650},"obj":"Disease"},{"id":"151","span":{"begin":721,"end":724},"obj":"Disease"},{"id":"152","span":{"begin":1034,"end":1044},"obj":"Disease"},{"id":"153","span":{"begin":1091,"end":1119},"obj":"Disease"}],"attributes":[{"id":"A132","pred":"tao:has_database_id","subj":"132","obj":"Gene:3439"},{"id":"A133","pred":"tao:has_database_id","subj":"133","obj":"Tax:9606"},{"id":"A134","pred":"tao:has_database_id","subj":"134","obj":"Tax:2697049"},{"id":"A135","pred":"tao:has_database_id","subj":"135","obj":"Tax:9606"},{"id":"A136","pred":"tao:has_database_id","subj":"136","obj":"Tax:9606"},{"id":"A137","pred":"tao:has_database_id","subj":"137","obj":"Tax:9606"},{"id":"A138","pred":"tao:has_database_id","subj":"138","obj":"Tax:9669"},{"id":"A139","pred":"tao:has_database_id","subj":"139","obj":"Tax:10090"},{"id":"A140","pred":"tao:has_database_id","subj":"140","obj":"Tax:694009"},{"id":"A141","pred":"tao:has_database_id","subj":"141","obj":"MESH:C558899"},{"id":"A142","pred":"tao:has_database_id","subj":"142","obj":"MESH:C023676"},{"id":"A143","pred":"tao:has_database_id","subj":"143","obj":"MESH:D012254"},{"id":"A144","pred":"tao:has_database_id","subj":"144","obj":"MESH:C086979"},{"id":"A145","pred":"tao:has_database_id","subj":"145","obj":"MESH:C558899"},{"id":"A146","pred":"tao:has_database_id","subj":"146","obj":"MESH:C000657245"},{"id":"A147","pred":"tao:has_database_id","subj":"147","obj":"MESH:C000657245"},{"id":"A148","pred":"tao:has_database_id","subj":"148","obj":"MESH:D011014"},{"id":"A149","pred":"tao:has_database_id","subj":"149","obj":"MESH:C000657245"},{"id":"A150","pred":"tao:has_database_id","subj":"150","obj":"MESH:D007239"},{"id":"A151","pred":"tao:has_database_id","subj":"151","obj":"MESH:D015658"},{"id":"A152","pred":"tao:has_database_id","subj":"152","obj":"MESH:D007239"},{"id":"A153","pred":"tao:has_database_id","subj":"153","obj":"MESH:D012141"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Till date, research has identified more than 30 therapeutic agents, including natural products, allopathic drugs and traditional Chinese medicines which could potentially be effective against COVID-19. For initial treatment of COVID-19, the People's Republic of China National Health Commission (NHC) has included antiviral agents including interferon α (IFN-α), lopinavir/ritonavir, chloroquine phosphate, ribavirin and arbidol in the revised edition of the guidelines for the prevention, diagnosis and treatment of novel coronavirus-induced pneumonia. Combinations of protease inhibitor(s) lopinavir/ritonavir for the treatment of COVID-19 infected patients have been evaluated which have been used previously to treat HIV patients (Liu et al., 2020). In several animal models, including non-human primates (Fouchier et al., 2003; Kuiken et al., 2003; McAuliffe et al., 2004; Rowe et al., 2004), ferrets (Martina et al., 2003), mice (Glass et al., 2004; Hogan et al., 2004) and Syrians hamsters (Roberts et al., 2005), experimental infections with SARS-CoV have been found to cause severe respiratory tract infections."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T5","span":{"begin":543,"end":552},"obj":"Phenotype"},{"id":"T6","span":{"begin":1091,"end":1119},"obj":"Phenotype"}],"attributes":[{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0011947"}],"text":"Till date, research has identified more than 30 therapeutic agents, including natural products, allopathic drugs and traditional Chinese medicines which could potentially be effective against COVID-19. For initial treatment of COVID-19, the People's Republic of China National Health Commission (NHC) has included antiviral agents including interferon α (IFN-α), lopinavir/ritonavir, chloroquine phosphate, ribavirin and arbidol in the revised edition of the guidelines for the prevention, diagnosis and treatment of novel coronavirus-induced pneumonia. Combinations of protease inhibitor(s) lopinavir/ritonavir for the treatment of COVID-19 infected patients have been evaluated which have been used previously to treat HIV patients (Liu et al., 2020). In several animal models, including non-human primates (Fouchier et al., 2003; Kuiken et al., 2003; McAuliffe et al., 2004; Rowe et al., 2004), ferrets (Martina et al., 2003), mice (Glass et al., 2004; Hogan et al., 2004) and Syrians hamsters (Roberts et al., 2005), experimental infections with SARS-CoV have been found to cause severe respiratory tract infections."}

{"project":"LitCovid-sentences","denotations":[{"id":"T42","span":{"begin":0,"end":201},"obj":"Sentence"},{"id":"T43","span":{"begin":202,"end":553},"obj":"Sentence"},{"id":"T44","span":{"begin":554,"end":753},"obj":"Sentence"},{"id":"T45","span":{"begin":754,"end":1120},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Till date, research has identified more than 30 therapeutic agents, including natural products, allopathic drugs and traditional Chinese medicines which could potentially be effective against COVID-19. For initial treatment of COVID-19, the People's Republic of China National Health Commission (NHC) has included antiviral agents including interferon α (IFN-α), lopinavir/ritonavir, chloroquine phosphate, ribavirin and arbidol in the revised edition of the guidelines for the prevention, diagnosis and treatment of novel coronavirus-induced pneumonia. Combinations of protease inhibitor(s) lopinavir/ritonavir for the treatment of COVID-19 infected patients have been evaluated which have been used previously to treat HIV patients (Liu et al., 2020). In several animal models, including non-human primates (Fouchier et al., 2003; Kuiken et al., 2003; McAuliffe et al., 2004; Rowe et al., 2004), ferrets (Martina et al., 2003), mice (Glass et al., 2004; Hogan et al., 2004) and Syrians hamsters (Roberts et al., 2005), experimental infections with SARS-CoV have been found to cause severe respiratory tract infections."}